Published in J Alzheimers Dis on January 01, 2012
Metformin in Amnestic Mild Cognitive Impairment (MCI) | NCT00620191
Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI) (POEM) | NCT00736996
Rosiglitazone Effects on Cognition for Adults in Later Life (RECALL) | NCT00242593
Exergaming Versus Aerobic Exercises on Mild Cognitive Impairment | NCT04127448
Cerebral structural changes in diabetic kidney disease: African American-Diabetes Heart Study MIND. Diabetes Care (2014) 0.98
Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology (2013) 0.98
Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. Clin Interv Aging (2015) 0.93
Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol Neurodegener (2014) 0.93
Inflammation-associated declines in cerebral vasoreactivity and cognition in type 2 diabetes. Neurology (2015) 0.85
Relationships among serum C-reactive protein, receptor for advanced glycation products, metabolic dysfunction, and cognitive impairments. BMC Neurol (2013) 0.84
Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease? Int J Alzheimers Dis (2012) 0.82
Complications of Diabetes. J Diabetes Res (2015) 0.80
Antibodies to the α1-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography. PLoS One (2012) 0.79
Increased protein aggregation in Zucker diabetic fatty rat brain: identification of key mechanistic targets and the therapeutic application of hydrogen sulfide. BMC Cell Biol (2014) 0.79
Metabolic relationship between diabetes and Alzheimer's Disease affected by Cyclo(His-Pro) plus zinc treatment. BBA Clin (2016) 0.78
Analysis of neuron-astrocyte metabolic cooperation in the brain of db/db mice with cognitive decline using 13C NMR spectroscopy. J Cereb Blood Flow Metab (2016) 0.78
First translational 'Think Tank' on cerebrovascular disease, cognitive impairment and dementia. J Transl Med (2016) 0.77
Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic rats. Am J Neurodegener Dis (2016) 0.77
Molecular interaction between type 2 diabetes and Alzheimer's disease through cross-seeding of protein misfolding. Mol Psychiatry (2017) 0.76
Abnormal myosin phosphatase targeting subunit 1 phosphorylation and actin polymerization contribute to impaired myogenic regulation of cerebral arterial diameter in the type 2 diabetic Goto-Kakizaki rat. J Cereb Blood Flow Metab (2015) 0.76
Decreased neuronal bursting and phase synchrony in the hippocampus of streptozotocin diabetic rats. J Diabetes Res (2014) 0.76
The negative effects of obesity and poor glycemic control on cognitive function: a proposed model for possible mechanisms. Curr Diab Rep (2014) 0.76
Obesity and Hepatic Steatosis Are Associated with Elevated Serum Amyloid Beta in Metabolically Stressed APPswe/PS1dE9 Mice. PLoS One (2015) 0.75
Folic acid attenuates cognitive dysfunction in streptozotocin-induced diabetic rats. Int J Clin Exp Med (2014) 0.75
Stroke Symptoms With Absence of Recognized Stroke Are Associated With Cognitive Impairment and Depressive Symptoms in Older Adults With Diabetes. J Geriatr Psychiatry Neurol (2016) 0.75
Retracted Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease. Am J Neurodegener Dis (2016) 0.75
Insulin signaling controls neurotransmission via the 4eBP-dependent modification of the exocytotic machinery. Elife (2016) 0.75
Dopamine pathway gene variants may modulate cognitive performance in the DHS - Mind Study. Brain Behav (2016) 0.75
Amylin: what might be its role in Alzheimer's disease and how could this affect therapy? Expert Rev Proteomics (2013) 0.75
Glycemic control, cognitive function, and family support among middle-aged and older Hispanics with diabetes: The Hispanic Community Health Study/Study of Latinos. Diabetes Res Clin Pract (2016) 0.75
Racial-ethnic disparities in the association between risk factors and diabetes: The Northern Manhattan Study. Prev Med (2015) 0.75
Functional MRI signal fluctuations: a preclinical biomarker for cognitive impairment in type 2 diabetes? Diabetes (2014) 0.75
Steps to Health in Cognitive Aging: Effects of Physical Activity on Spatial Attention and Executive Control in the Elderly. Front Hum Neurosci (2017) 0.75
Hyperamylinemia as a risk factor for accelerated cognitive decline in diabetes. Expert Rev Proteomics (2015) 0.75
Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study. Clin Transl Med (2017) 0.75
The diabetic brain and cognition. J Neural Transm (Vienna) (2017) 0.75
Word-stem priming and recognition in type 2 diabetes mellitus, Alzheimer's disease patients and healthy older adults. Exp Brain Res (2015) 0.75
Reduced Gray Matter Volume in Patients with Type 2 Diabetes Mellitus. Front Aging Neurosci (2017) 0.75
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Prevalence of overweight and obesity in the United States, 1999-2004. JAMA (2006) 72.59
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med (2001) 56.11
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA (2003) 25.44
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (2009) 15.00
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04
Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet (2006) 11.64
Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychol Sci (2003) 11.59
Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA (1997) 10.75
Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med (2003) 10.61
Lifetime risk for diabetes mellitus in the United States. JAMA (2003) 10.33
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health (1998) 9.58
Thiazolidinediones. N Engl J Med (2004) 9.42
Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology (2007) 9.27
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA (1989) 8.36
Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes (1988) 7.80
Metformin. N Engl J Med (1996) 7.66
Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology (1999) 7.55
Alzheimer's disease. N Engl J Med (2004) 7.50
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Age, neuropathology, and dementia. N Engl J Med (2009) 6.36
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med (2005) 5.76
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A (2003) 5.44
Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med (2008) 5.34
Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation (2006) 5.31
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Midlife cardiovascular risk factors and risk of dementia in late life. Neurology (2005) 5.12
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol (2004) 5.11
Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes (2002) 4.97
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81
The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA (2004) 4.73
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron (2004) 4.29
Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology (2005) 4.04
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res (2004) 4.00
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J (2006) 3.92
Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology (2006) 3.68
Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol (2004) 3.67
Stroke and the risk of Alzheimer disease. Arch Neurol (2003) 3.49
Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol (2001) 3.43
The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta (2000) 3.33
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging (2005) 3.32
Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci (2002) 3.26
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol (2011) 3.25
Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology (2006) 3.22
Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol (2000) 3.05
The obesity epidemic: pathophysiology and consequences of obesity. Obes Res (2002) 3.04
Cognition and diabetes: a lifespan perspective. Lancet Neurol (2008) 2.96
Hyperinsulinemia and risk of Alzheimer disease. Neurology (2004) 2.87
American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke (1997) 2.87
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Relation of diabetes to mild cognitive impairment. Arch Neurol (2007) 2.86
High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA (2001) 2.85
Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology (2004) 2.81
Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes (2006) 2.77
Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol (1997) 2.60
Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology (2006) 2.48
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes (2005) 2.46
The dementias. Lancet (2002) 2.42
Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res (2007) 2.39
Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med (2007) 2.32
Insulin increases CSF Abeta42 levels in normal older adults. Neurology (2003) 2.27
Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry (2005) 2.21
Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging (2005) 2.15
Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol (1999) 2.13
Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology (2004) 2.10
Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology (2006) 2.06
Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med (2005) 2.05
Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol (2008) 2.04
Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol (2008) 1.97
Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord (2002) 1.95
RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol (2006) 1.94
The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann Neurol (2008) 1.92
Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) (1998) 1.90
Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med (2009) 1.90
Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol (2001) 1.89
The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol (2007) 1.85
Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs (1995) 1.82
Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A (1994) 1.82
Mild cognitive impairment: directions for future research. Neurology (2003) 1.78
Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A (2009) 1.76
Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol (2009) 1.76
Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol (2008) 1.74
Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology (2004) 1.70
Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). Diabetes Care (2008) 1.69
Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci (2004) 1.62
The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes (2007) 1.62
Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke (2003) 1.61
Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. J Neurosci (2010) 1.58
Mild cognitive impairment: prevalence and incidence according to different diagnostic criteria. Results of the Leipzig Longitudinal Study of the Aged (LEILA75+). Br J Psychiatry (2003) 1.58
Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr (2007) 1.56
Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging (2006) 1.56
Insulin resistance and Alzheimer's disease. BMB Rep (2009) 1.49
Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol (1998) 1.47
Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes (2003) 1.46
Diabetes, related conditions, and dementia. J Neurol Sci (2010) 1.08